Aptevo Therapeutics EPS - Earnings per Share 2014-2022 | APVO
Aptevo Therapeutics eps - earnings per share from 2014 to 2022. Eps - earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.
Aptevo Therapeutics Annual EPS |
2021 |
$-6.07 |
2020 |
$-5.23 |
2019 |
$-13.86 |
2018 |
$-33.47 |
2017 |
$4.62 |
2016 |
$-77.73 |
2015 |
$-41.04 |
2014 |
$0.00 |
2013 |
$0.00 |
Aptevo Therapeutics Quarterly EPS |
2022-03-31 |
$-1.55 |
2021-12-31 |
$-1.25 |
2021-09-30 |
$-1.43 |
2021-06-30 |
$-1.75 |
2021-03-31 |
$-1.64 |
2020-12-31 |
$-1.92 |
2020-09-30 |
$-2.10 |
2020-06-30 |
$-2.10 |
2020-03-31 |
$0.89 |
2019-12-31 |
$0.07 |
2019-09-30 |
$-2.15 |
2019-06-30 |
$-4.14 |
2019-03-31 |
$-7.64 |
2018-12-31 |
$-8.82 |
2018-09-30 |
$-7.70 |
2018-06-30 |
$-8.12 |
2018-03-31 |
$-8.82 |
2017-12-31 |
$-5.74 |
2017-09-30 |
$24.51 |
2017-06-30 |
$-7.42 |
2017-03-31 |
$-6.72 |
2016-12-31 |
$-10.22 |
2016-09-30 |
$-49.72 |
2016-06-30 |
$-8.82 |
2016-03-31 |
$-8.96 |
2015-12-31 |
$0.00 |
2015-09-30 |
$-8.82 |
2015-06-30 |
$-12.33 |
2014-12-31 |
$0.00 |
2013-12-31 |
$0.00 |
Sector |
Industry |
Market Cap |
Revenue |
Medical |
Medical - Biomedical and Genetics |
$0.022B |
$0.012B |
Aptevo Therapeutics Inc. is a biotechnology company which focused on developing oncology and hematology therapeutics. The company's platform consists of ADAPTIR(TM). Its product pipeline includes WinRho (R) SDF, HepaGam B (R), VARIZIG(R) and IXINITY (R) which are in pre-clinical stage. Aptevo Therapeutics Inc. is based in Seattle, Washington.
|